UPDATE: PTC Therapeutics (PTCT) Initiated Neutral at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
PTC Therapeutics (PTCT) Misses Q3 EPS by 97c, Revenues Beat
October 29, 2020 5:14 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.03), $0.97 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $118.4 million versus the consensus estimate of $112.21 million.
"I am very pleased by the rapid progress that we have made this... More
